⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

Comparative Efficacy of Opicapone and Entacapone in the Management of Motor Fluctuations in Parkinson’s Disease (P3-17.002)

Stuart Isaacson Fahd Amjad Sandeep Thakkar Bruno Dias Helena Brigas Bita Naderi Ghazal Banisadr Stanley Fisher

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate and compare the clinical efficacy of opicapone and entacapone in managing motor fluctuations in patients with Parkinson’s disease.
Compared efficacy of opicapone and entacapone as COMT inhibitors
Examined their effects on motor fluctuations in patients with Parkinson’s disease
Opicapone showed a statistically significant improvement in motor fluctuations compared to entacapone
Details on exact numeric outcomes were not provided

Implication

Compares effectiveness of opicapone and entacapone for motor fluctuations in Parkinson’s disease, indicating potential treatment options.

Abstract

To compare the clinical efficacy of two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Isaacson et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf32afaef96ed7f055a0f https://doi.org/10.1212/wnl.0000000000215249

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Cost-Effectiveness of Opicapone Versus Entacapone as Adjuvant Therapy for Levodopa-Treated Individuals With Parkinson's Disease Experiencing End-of-Dose Motor Fluctuations.2025
2Entacaponereview · 2000 · 13 citations
3Disease Stage and Motor Fluctuation Duration Predict Drug Tolerability: A Real-Life, Prospective Italian Multicenter Study on the Use of Opicapone in Parkinson’s Disease2024 · 6 citations
4Opicapone in Parkinson’s patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON studyOriginal Research · 2026
5COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion2025 · 7 citations